A Study of Galcanezumab in Healthy Participants

• Status: Completed
• Trial end date: 2018-01-08
• Target enrollment: 0
• Participant gender: All

Summary

The purposes of this study are:

• To evaluate tolerability of the Galcanezumab solution injectable formulation (Part A)

• To measure how much of the Galcanezumab lyophilized (freeze dried) injectable formulation is absorbed into the blood stream and how long it takes the body to get rid of it compared to the Galcanezumab solution injectable formulation after a single injection under the skin (subcutaneous [SC]) (Part B).

Information about any side effects that may occur will also be collected. Each part of the study will last about six months. Participants may only enroll in one part.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Male and female healthy participants

• Have a body mass index of 19.0 to 35.0 kilograms per meter square (kg/m²), inclusive

Exclusion Criteria:

• Currently smoke in excess of 5 cigarettes/day